Project Grant R01CA296911
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $663K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, DC, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) provides $547,047 to Georgetown University to conduct a clinical trial testing the bundling of multicancer screening and genetic services navigation to improve cancer health equity among Black and Hispanic women. The project aims to address patient- and organization-level barriers that limit cancer screening and genetic testing rates in these populations, which experience...
- The University of Southern California was awarded a $613,220 Project Grant under the National Cancer Institute's Cancer Cause and Prevention Research (CFDA 93.393) program. The grant, which runs from February 1, 2025 to January 31, 2030, will fund research to investigate the contribution of germline copy number variations to the susceptibility of aggressive prostate cancer in men of African and European ancestry. The project aims to leverage existing genome-wide association study, whole-exome...
- The University of Southern California (USC) received a $704,882 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to define the genetic factors underlying familial prostate cancer in African American (AA) men. The project aims to develop improved risk prediction models that incorporate polygenic risk scores, pathogenic variants, and family history of prostate cancer for the AA population. By leveraging existing...
- This federal Project Grant award of $635,033, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research program), supports research to understand the genetic basis of a newly recognized cancer-prone syndrome caused by long telomere length. The award was granted to The Johns Hopkins University, a leading federal research contractor, to conduct comprehensive investigations into this genetic mechanism driving cancer development, which is distinct from tumor...
- The U.S. National Cancer Institute (NCI) awarded a 5-year, $680,433 Project Grant to the University of California, San Francisco (UCSF) under the NCI's Cancer Detection and Diagnosis Research (CFDA 93.394) program. The grant supports research aimed at using cutting-edge spatial proteogenomic technologies and pathology artificial intelligence (PAI) to improve prognostic estimation and elucidate the underlying biology driving PAI outcomes in prostate cancer. The project seeks to: 1) understand the...
- This $564,543 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research federal grant program (CFDA 93.393). The grant supports research at the Weill Medical College of Cornell University to investigate how the androgen receptor (AR) governs normal, growth-suppressive gene expression in prostate cells, and how this program becomes hijacked to drive oncogenic transcription in prostate cancer. The research aims to determine if the normal,...
- The University of Pennsylvania received a $371,719 Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research program) to conduct research towards characterizing epigenetic targets in prostate cancer. The 5-year project, awarded on March 1, 2025, aims to identify, characterize, and therapeutically target co-factors and chromatin-associated proteins involved in the androgen receptor signaling pathway in prostate cancer. Specifically, the research will...
- This $231,413 federal Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), on April 7, 2025. The grant supports a research project to establish in vitro models that recapitulate the carcinogenic process of human germ cell neoplasia in situ (GCNIS), which are precursor lesions for most testicular germ cell tumors. The project aims to...
- This Project Grant award, totaling $354,658, was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Johns Hopkins University. The objective is to perform a systematic analysis of P27 alterations in both primary and metastatic prostate cancer, with the ultimate aim of understanding how subclonal P27 loss mediates worse prostate cancer outcomes, particularly in African American males who experience higher mortality rates from the disease. This research...
- The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...